| Date | Title | Description |
| 19.02.2026 | S&P 500 rises, Dow gains 200 points after Supreme Court strikes down Trump emergency tariffs: Live updates | Stocks rose on Friday after the Supreme Court ruled against President Donald Trump’s tariffs, potentially providing relief for companies burdened by higher costs from the duties and easing concern about sticky inflation still plaguing the U... |
| 12.11.2025 | Hepta Unveils AI Liquid Biopsy for Chronic Disease | Hepta secures $6.7M. It pioneers AI-driven liquid biopsy for chronic diseases, starting with MASH. Its transformer AI platform analyzes cell-free DNA epigenomes. This delivers unparalleled precision in diagnosis. The non-invasive blood test... |
| 10.11.2025 | Hepta Emerges from Stealth with $6.7M to Pioneer AI-Driven Chronic Disease Liquid Biopsy | What You Should Know:
– Hepta, a biotechnology company focused on diagnosing chronic disease, has emerged from stealth announcing $6.7M in seed funding co-led by Felicis Ventures and Illumina Ventures, with participation from SeaX Ventures,... |
| 06.11.2025 | Hepta: $6.7 Million Seed Funding Closed To Advance Liquid Biopsy-Based AI Diagnostics For Chronic Liver Disease | Hepta, a biotechnology company developing a transformer-based artificial intelligence platform to analyze the cell-free DNA epigenome, has emerged from stealth with $6.7 million in seed funding. The round was led by Felicis Ventures and Ill... |
| 31.10.2025 | Curve Biosciences Ignites New Era in Chronic Disease Care with $40M Funding | Curve Biosciences recently secured $40M in Series A funding. This capital fuels its Whole-Body Intelligence platform. The platform uses the proprietary Whole-Body Atlas, a vast collection of tissue samples. It powers advanced Whole-Body Blo... |
| 30.10.2025 | Curve Biosciences: $40 Million Raised To Advance Whole-Body Intelligence Platform for Chronic Disease Monitoring | Curve Biosciences, a biotechnology company pioneering Whole-Body Intelligence for proactive and personalized chronic disease care, has raised $40 million in new funding led by Luma Group, with participation from First Spark Ventures, Techas... |
| 29.10.2025 | Curve Biosciences Secures $40M to Launch Whole-Body Intelligence Platform | What You Should Know:
– Curve Biosciences, the Whole-Body Intelligence™ company, today announced it has raised $40M in Series A funding led by Luma Group, with participation from First Spark Ventures, Techas Capital, Civilization Ventures, ... |
| 26.10.2025 | GRAIL raises $325 million in private placement | GRAIL GRAIL
Founded: 2016
Headquarters: Menlo Park, California, United States
Total Funding: $2.44B
See full company profile "> , the Menlo Park–based healthcare company focused on early cancer detection, announced a $325 million pr... |
| 19.10.2025 | Samsung to bring GRAIL’s cancer test to Asia | Samsung C&T and Samsung Electronics Samsung Electronics
Founded: 1969
Headquarters: Seoul, Seoul-t'ukpyolsi, South Korea
Total Funding: $4.75B
See full company profile "> signed a binding agreement with GRAIL GRAIL
Founded: 2016... |
| 11.12.2024 | The AI Revolution: Transforming Healthcare and IT for a New Era | Artificial Intelligence (AI) is not just a buzzword; it’s a tidal wave reshaping industries. In healthcare and IT, AI is the engine driving efficiency, precision, and innovation. The transformation is profound, with each sector harnessing A... |
| 11.12.2024 | AI transforming healthcare with better outcomes & efficiency | The healthcare industry is experiencing significant changes driven by advancements in artificial intelligence (AI), which is altering how care is delivered and improving patient outcomes.
The global AI in healthcare market is on a growth pa... |
| 29.11.2024 | EU regulators scrap merger power aimed at killer acquisitions after court veto | EU regulators scrap merger power aimed at killer acquisitions after court veto
By Foo Yun CheeNovember 29, 20245:13 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
An Illumina office building is... |
| 20.11.2024 | INITIATE Ventures: $45 Million Closed For Funding Health Tech And Life Sciences Companies | INITIATE Ventures announced the closing of $45 million in its debut venture capital fund and affiliated company creation platform. And INITIATE invests in and co-founds transformative companies at the intersection of healthcare, life scienc... |
| 18.11.2024 | INITIATE Ventures Closes $45 Million to Fund and Co-create Companies at the Intersection of Healthcare, Life Sciences, and Tech | Led by serial founders, INITIATE partners with exceptional leaders to build bold companies that solve vital healthcare challenges
SAN FRANCISCO, Nov. 18, 2024 /PRNewswire-PRWeb/ -- Today, INITIATE Ventures announced the close of $45 million... |
| 04.06.2024 | Illumina approves Grail spinoff plan | figcaption>span]:font-sans">
Illumina on Tuesday said its board has approved plans to spin off Grail, the early cancer screening company it founded, spun off, and then reacquired for $8 billion over the objections of antitrust re... |
| 22.05.2024 | SquareX Shines Bright at Cyber Entrepreneurship Summit 2024 | A rising star in the cybersecurity realm, SquareX, dazzled attendees at the Cyber Entrepreneurship Summit 2024 with its innovative browser-native security solution. The event, held at the Nasdaq Entrepreneurial Center in San Francisco, saw ... |
| 21.05.2024 | SquareX Recognized as 'Most Promising Startup for Best Overall Performance' at Cyber Entrepreneurship Summit 2024. | SINGAPORE, May 21, 2024 /PRNewswire/ -- SquareX, with its innovative browser native security solution, was awarded the "Most Promising Startup for Best Overall Performance" at the Cyber Entrepreneurship Summit held at Nasdaq Entre... |
| 21.05.2024 | SquareX Recognized as 'Most Promising Startup for Best Overall Performance' at Cyber Entrepreneurship Summit 2024. | SINGAPORE, May 21, 2024 /PRNewswire/ -- SquareX, with its innovative browser native security solution, was awarded the "Most Promising Startup for Best Overall Performance" at the Cyber Entrepreneurship Summit held at Nasdaq Entre... |
| 16.05.2024 | Fitness Enthusiast Unexpectedly Finds Cancer through New Screening Test | (BPT) - Putting Health First
Gym owner and avid fitness enthusiast, Rich, has always prioritized his health. He prides himself on being health conscious, taking steps to maintain his health and keeping up with his annual exams.
After learni... |
| 25.04.2024 | Business | FTC chief says tech advancements risk health care price fixing | Julie Rovner, David Hilzenrath | (TNS) KFF Health News
New technologies are making it easier for companies to fix prices and discriminate against individual consumers, the Biden administration’s top consumer watchdog said Tuesday.
Algorithm... |
| 09.08.2023 | Медицина 2.0, которая изменит наше будущее | Наткнулся тут на новый выпуск журнала Wired.
Ну вот небольшой список из новых открытий и интересных компаний:
1 комментарий
105 просмотров
онлайн-клиника для женщин и будущих мам, которая закрыла раунд на 250 миллионов долларов;
генотерапия... |
| 26.07.2023 | Why Digital Biology Has the Power to Change the Game Across Industries | Is digital biology the next big thing? In a world where AI services like ChatGPT and Midjourney dominate the hype cycle, this might sound like quite the claim. But it’s based on a solid foundation. As digital biology tools continue to evolv... |
| 19.10.2022 | Carrum Health, GRAIL strike up partnership to offer cancer test to employers | As cancer becomes the leading condition driving up employers’ costs, two companies are teaming up to combat the issue.
The partnership is between digital health company Carrum Health and biotechnology company GRAIL. Carrum is a value-based ... |
| 18.10.2022 | Viome Life Sciences snags $67M to expand DTC pipeline of at-home tests and wellness products | Biotechnology company Viome Life Sciences will be expanding its development of direct-to-consumer diagnostic tests and wellness products after receiving $67 million in series C funding, the startup announced Tuesday.
Bellevue, Washington-ba... |
| 14.10.2022 | StartUPDATES: New developments from healthcare startups | Memory Health, the only supplement patented for the prevention and/or treatment of neurodegenerative disease, has been proven in another independent clinical study, showing benefits in patients with mild-moderate Alzheimer’s disease. The st... |
| 13.10.2022 | GRAIL, Carrum Health Partners to Help Employers Address Cancer Care | What You Should Know: |
| 25.07.2021 | Would Illumina’s acquisition of GRAIL constrict the expansion of the liquid biopsy space? | Earlier this year, the Federal Trade Commission’s (FTC) posed a roadblock in the path of sequencing giant Illumina’s $7.1 billion proposed acquisition of Grail, a healthcare company focusing on early cancer detection, and importantly, a 201... |
| 05.06.2021 | Ally Bridge Portfolio News – GRAIL Presents Interventional PATHFINDER Study Data at 2021 ASCO Annual Meeting and Introduces Galleri, a Groundbreaking Multi-Cancer Early Detection Blood Test | — Galleri’s ability to detect more than 50 types of cancer with a single blood draw could transform early cancer detection as a complement to existing screenings; test now available in U.S. by prescription only —
MENLO PARK, Calif., June 4... |
| 02.04.2021 | An antitrust expert weighs in on the FTC’s complaint against Illumina | Spare a thought for Illumina. The $56 billion dollar titan of genomics has become the world’s leading supplier of DNA sequencing technology. That’s been great for the company’s bottom line over the years. But Illumina’s market dominance is ... |
| 25.02.2021 | New blood test poised to change how cancer is found | (BPT) - Rare is the person who hasn't been impacted by cancer in some way. Maybe it's your parent fighting for their life. Perhaps it's a friend going through a difficult treatment. It could be a neighbor or colleague who was recently diagn... |
| 19.02.2021 | Power Moves: Meet Mia Millette, Skyline Technology Solutions’ new CEO | Power Moves is a column where we chart the comings and goings of talent across the region. Got a new hire, new gig or promotion? Tell us: baltimore@technical.ly.
Mia Millette was promoted to the CEO role at Glen Burnie-based Skyline Technol... |
| 09.02.2021 | What if one blood test could detect more than 50 types of cancers? | (BPT) - Everyone has been touched by cancer in some way, whether it's a friend or family member facing a diagnosis, or their own worry about susceptibility to the disease. This year alone, roughly 1.8 million people will be diagnosed with c... |
| 09.02.2021 | What if one blood test could detect more than 50 types of cancers? | (BPT) - Everyone has been touched by cancer in some way, whether it's a friend or family member facing a diagnosis, or their own worry about susceptibility to the disease. This year alone, roughly 1.8 million people will be diagnosed with c... |
| 04.02.2021 | New blood test poised to change how cancer is found | (BPT) - Rare is the person who hasn't been impacted by cancer in some way. Maybe it's your parent fighting for their life. Perhaps it's a friend going through a difficult treatment. It could be a neighbor or colleague who was recently diagn... |
| 04.01.2021 | Genetic testing company Color raises $167M to roll out COVID vaccines | The company partnered with state and local governments to power their COVID testing initatives
COVID is going to have a profound effect on the healthcare space; some of those effects are showing themselves, such as with the rise of teleheal... |
| 30.12.2020 | Medical innovations poised to transform healthcare in 2021 | (BPT) - Experts in healthcare are continuously striving to develop new innovations that can improve and save lives. Even amidst the COVID-19 pandemic, scientists, physicians, and researchers continued to advance medical knowledge, enhance s... |
| 30.12.2020 | Medical innovations poised to transform healthcare in 2021 | (BPT) - Experts in healthcare are continuously striving to develop new innovations that can improve and save lives. Even amidst the COVID-19 pandemic, scientists, physicians, and researchers continued to advance medical knowledge, enhance s... |
| 03.11.2020 | Healthcare startups: what they've been up to this year | Amwell went public, Livongo merged with Teladoc and Grail got acquired
COVID caused all sorts of problems for the healthcare space this year, but it also created opportunity. That's why the third quarter of 2020 set a record for investment,... |
| 06.10.2020 | The role of precision medicine in the pandemic response | Investments into precision medicine companies is rising, but how much has it helped?
What healthcare will look like when the COVID pandemic is over is tough to say right now. What new technologies will emerge from this? What new data sets a... |
| 21.09.2020 | Illumina buying cancer-screening spinout Grail in blockbuster $8B biotech deal | Biotech has become one of the hottest areas of venture investment in recent years, as progress in machine learning, genetics, medical devices and biology fuse together into new products for the gargantuan health industry.
Case in point: Gra... |
| 09.05.2020 | Ally Bridge Portfolio News – GRAIL Announces $390 Million Series D Financing | MENLO PARK, Calif. — (BUSINESS WIRE) — GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced a $390 million Series D financing round. New investors including Public Sector Pension I... |
| 07.05.2020 | Grail's 4th funding round nets $390M for its cancer-seeking blood test | Grail has secured its fourth nine-digit-plus financing round, bringing its total funding to nearly $2 billion as it looks to complete the clinical testing of its cancer-seeking blood test.
The latest series D financing brought in $390 milli... |
| 07.05.2020 | Blood test for cancer detection company Grail rakes in $390M in latest round | Just over a week after Third Rock-backed Thrive unveiled ‘real world’ data from a large study evaluating the ability of its blood test to sniff out early signs of cancer in individuals with no history of the disease, riva... |
| 07.05.2020 | Grail's 4th funding round nets $390M for its cancer-seeking blood test
W h i t e p a p e r
Vital Precision for Cost Reduction, QA, and Regulatory Compliance | Grail has secured its fourth nine-digit-plus financing round, bringing its total funding to nearly $2 billion as it looks to complete the clinical testing of its cancer-seeking blood test.
Sponsored by Agilent Technologies
How would you lik... |
| 06.05.2020 | Grail Raises $390M in Series D Financing | Grail, Inc., a Menlo Park, California and Washington, D.C.-based healthcare company which aims to find solutions to detect cancer early, when it can be cured, raised $390m in Series D funding.
Backers included new investors Public Sector Pe... |
| 04.12.2019 | Venclose closes $27m Series C | Venous reflux disease treatment developer Venclose announced that it closed a Series C funding round totaling $27 million.
Venclose develops the next-generation Venclose RF ablation system designed to close damaged veins and restore healthy... |
| 08.10.2019 | Grail validation data show highly accurate detection of cancers, tissues of origin | “Today, cancer remains the second leading cause of death worldwide, and we believe an effective multi-cancer early detection technology has the potential to transform the cancer care landscape,” Grail CEO Hans Bishop said in a statement.
Th... |
| 24.07.2019 | Freenome nabs $160M to advance blood-based colorectal cancer test | Other new investors in the round include Roche Venture Fund, Kaiser Permanente Ventures and the social impact investing arm of the American Cancer Society. The company has raised a total of $238 million since its founding in 2014.
Alongside... |
| 20.06.2019 | Isilon co-founder Sujal Patel building mysterious biotech startup, backed by Andreessen Horowitz | Sujal Patel. (GeekWire File Photo)
Sujal Patel has seen a world-changing trend coming before.
In 2001, in his mid-20s, he founded data storage technology company Isilon Systems in Seattle, correctly anticipating a massive increase in unstru... |
| 31.05.2019 | Grail’s liquid biopsy test shows high sensitivity in early cancer detection | The early-stage cancers – meaning stages I-III – included anorectal, colorectal, esophageal, head and neck, hormone receptor-negative breast, liver, lung, ovarian and pancreatic, as well as some blood cancers, namely multiple myeloma and ly... |
| 30.05.2019 | Liquid biopsy firm Thrive launches with $110M Series A round | Third Rock Ventures led the round, with participation by Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, Invus, Exact Sciences, Cowin Venture, Camden Partners and Gamma 3, among others.
The company’s fo... |
| 26.04.2019 | Роботаблетки, карманное УЗИ, синтетические микробы, лекарство от старости и ещё 21 перспективная разработка медстартапов Статьи редакции... | Как изменится медицина в ближайшем будущем.
10 10 комментариев
14 649 просмотров
Слушать
По данным PitchBook, медицинские стартапы привлекли более $28,7 млрд за 2018 год. В подборке — «единороги-революционеры», которые не только привлекли м... |
| 09.10.2018 | SplashX Precision Health: making sense of the data | How do entrepreneurs and investors in precision health see data making a difference?
One of the big themes to come up repeatedly during Vator's salon, SplashX Invent Health - Precision Health, co-hosted and co-produced by HP, was data, incl... |
| 24.09.2018 | На что тратит деньги Билл Гейтс: вода из фекалий, борьба с болезнью Альцгеймера и другие инвестиции Статьи редакции... | В какие проекты вкладывает один из самых богатых людей мира.
70 70 комментариев
21 068 просмотров
Благотворительность
В 1994 году Билл и Мелинда Гейтс основали Фонд Уильяма Гейтса, чтобы поддерживать образование и здравоохранение, помогать ... |
| 25.05.2018 |
Illumina Spinout Grail Gets $300M More For Cancer Detection Testing
| Grail, the spinout of San Diego-based life sciences equipment maker Illumina, has raised $300M more in funding, the company said this week. The startup is developing blood testing technology which uses DNA analysis to help in early detectio... |
| 23.05.2018 | Ally Bridge Portfolio News – Ally Bridge Group Leads GRAIL’s $300 Million Series C Financing | HONG KONG, May 21, 2018 /PRNewswire/ — Ally Bridge Group, a global life science-focused investment group, today announced that it has led a $300 million financing completed for GRAIL, Inc., a healthcare company whose mission is to detect ca... |
| 23.05.2018 | Term Sheet — Wednesday, May 23 | 5 Qs WITH A DEALMAKER
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
“When I looked around, I saw a lot of women who were starting businesses,” she told Term Sheet. “I recognized that in the... |
| 23.05.2018 | Ally Bridge Portfolio News – GRAIL Announces $300 Million Raised in Oversubscribed Series C Financing | MENLO PARK, Calif. & HONG KONG–(BUSINESS WIRE) — GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced it has raised USD$300 million in an oversubscribed Series C financing. The... |
| 22.05.2018 | Healthcare Company Grail Raises $300M in Financing | Grail, Inc., a Menlo Park, California and Hong Kong-based healthcare company developing solutions to detect cancer early, raised $300m in financing.
The round was led by Ally Bridge Group, a global life science-focused investment group, wit... |
| 05.05.2018 | A life sciences firm run by a top VC and a cofounder of Alphabet’s life sciences arm, just raised its biggest fund yet | There’s no end to the number of fascinating devices and therapies being created right now in the fields of health and life sciences. The investors behind them are often pretty interesting, too, given the expertise needed to make informed be... |
| 28.02.2018 | Term Sheet — Wednesday, February 28 | THE STATE OF PRIVATE EQUITY
Good morning, Term Sheet readers.
Paid Content What you need to know about growing cyberattacks From ExtraHop
—-
In lieu of Term Sheet’s ‘5 Qs With a Dealmaker’ this week, we feature a Q&A with Hugh MacArthur... |
| 01.02.2018 | Is too much money being invested in oncology? | Oncology is to funding as gravity is to everything else – but is it over the top? Is cancer investment too much, too little or just right?
“I’ve been asking this for a number of years,” said Jay Lichter, managing director at Avalon Ventures... |
| 12.01.2018 | Digital health investments reached record level in 2017 | Technology companies focused on the patient/consumer experience once again was the dominant category with 191 deals, according to StartUp Health.
Rock Health noted that 60 percent of the companies funded last year sell to providers.
Photo: ... |
| 14.12.2017 | ARCH Venture Partners-backed GRAIL Appoints Jennifer Cook as CEO | MENLO PARK, Calif.–(BUSINESS WIRE)–GRAIL, Inc., a life sciences company whose mission is to detect cancer early when it can be cured, today announced the appointment of Jennifer Cook as chief executive officer, effective January 2, 2018. Bi... |
| 31.10.2017 | Early cancer-detection startup Grail is reportedly trying to raise more money | Just months after Grail raised a $900 million Series B round, the startup that aims to detect cancer early on is looking for additional funding, CNBC reports. Prior to the $900 million round, Grail raised $100 million last year to develop i... |
| 31.05.2017 | Term Sheet — Wednesday, May 31 | CRYPTO BUBBLE, DIVERSITY, JOBS, BURNOUT
Good morning. Many, many private equity deals this morning, including two notable acquisitions for Vista Equity Partners and a $13.5 billion Blackstone exit that isn’t an IPO. Plus a new health-tech u... |
| 15.03.2017 | VC firm Biomatics Capital closes $200M fund focused on genomics and digital health | Seattle-based venture capital firm Biomatics Capital, which focuses on companies innovating around healthcare and technology, has closed its initiatory fund of $200 million. This exceeds the firm’s target of $150 million and spans a range o... |
| 03.03.2017 | Grail Raises Over $900M in Series B Financing | Grail, Inc., a Menlo Park, CA-based life sciences company that promises to detect cancer early when it can be cured, raised over $900m through the first close of its Series B funding.
The round was led by Arch Venture Partners with particip... |
| 01.03.2017 | Early cancer detection startup GRAIL closes on $900 million in Series B funding | Life sciences startups need a whole lot more cash than most and that’s certainly true for GRAIL, a cancer detection startup trying to figure out a way to find the “emperor of all maladies” much earlier through blood testing technology. The ... |
| 01.03.2017 | GRAIL Lands $900M for Early Cancer Detection | GRAIL, Inc., a life sciences company whose mission is to detect cancer early when it can be cured, today announced it has raised $900 million in Series B funding led by ARCH Venture Partners with participation from Johnson & Johnson Inn... |
| 01.03.2017 |
Illumina's GRAIL Raises $900M In Funding Round
| GRAIL, the cancer detection spinout of San Diego's Illumina, said this morning that it has raised $900M in a first close of a planned, $1 billion funding round. The Series B funding was led by Arch Venture Partners, and included Johnson and... |
| 01.02.2017 | 5 snippets from Illumina’s latest earnings call | For the final earnings numbers, the call transcript can be viewed here. If you’re after some company highlights, see below for five observations about where the next-gen biotech is at.
1) In a nutshell, the numbers were good
Revenue for the... |
| 20.01.2017 | This CEO has a promising startup but no visa | What she doesn’t have is a U.S. visa.
More specifically, Zanforlin doesn’t have the money to pay for the residency tuition that will grant her an H1-B work visa. It’s an added challenge that most entrepreneurs don’t have to face.
Born and r... |
| 17.01.2017 | Oncology, rare diseases and too little genomic diversity: 3 themes from #JPM17 | Beyond the conference agenda and the breaking news, however, three underground themes were playing out at Bioweek.
Genomic diversity
In back-to-back sessions, the issue of ethnic diversity in genomic research came to the fore. The original ... |
| 06.01.2017 |
Illumina Spinout Plans To Raise $1 Billion In Series B
| San Diego-based life sciences equipment maker Illumina says that its cancer detection spinout, GRAIL, is now expecting to raise approximately $1 billion in its Series B funding. GRAIL, which was founded by Illumina, is developing blood test... |
| 05.01.2017 | Grail is raising at least $1 billion to fund its early cancer screening test | The early cancer screening startup Grail plans to raise more than $1 billion in Series B financing, possibly up to $1.8 billion.
While the company doesn’t want to name investor names, only mentioning in a release the funding will come “prim... |
| - | Grail’s liquid biopsy test shows high sensitivity in early cancer detection | A company developing liquid biopsy technology for the early detection of cancers has new data that it is presenting Saturday at a major cancer conference.
Menlo Park, California-based Grail said it will have a poster presentation of early d... |
| - | Carl Icahn blasts Illumina for nearly doubling CEO’s pay despite steep drop in market value | Carl Icahn blasted Illumina for nearly doubling its CEO’s pay last year despite a dramatic drop in the biotech company’s market value since closing the controversial Grail deal.
Illumina CEO Francis DeSouza was awarded nearly $26.8 million ... |
| - | Carl Icahn claims Illumina directors got extra insurance to close ‘disastrous’ $7.1 billion Grail deal | Carl Icahn alleged that Illumina’s directors demanded extra personal liability insurance before the biotech company signed off on a $7.1 billion acquisition of cancer test developer Grail in 2021.
He also alleged the Illumina board decided ... |
| - | Biotech company Illumina pushes back against Carl Icahn’s proxy fight over $7.1 billion Grail deal | Illumina pushed back against Carl Icahn’s proxy fight over its $7.1 billion acquisition of cancer test developer Grail.
The DNA sequencing company said it’s committed to maximizing shareholder value as it works with antitrust regulators to ... |
| - | Illumina CEO touts Grail’s 100% revenue growth amid proxy fight with Icahn | Illumina CEO Francis deSouza touted the company’s controversial acquisition of Grail after revenue from the cancer test developer doubled in the past year.
The executive added the deal “makes sense” for San Diego-based Illumina, citing the ... |
| - | 5 snippets from Illumina’s latest earnings call | San Diego, California-based Illumina shared its Q4 and full-year earnings with investors on Tuesday, generating plenty of optimism for the year ahead.
None of the figures were that surprising, given Illumina had divulged preliminary estimat... |
| - | Illumina shareholders oust board chair, CEO survives Carl Icahn proxy battle | Illumina shareholders ousted board chairman John Thompson.
Carl Icahn had urged shareholders to oust both Thompson and CEO Francis deSouza. DeSouza survived the fight.
An Illumina spokesperson said a new board chair will be chosen in the ne... |
| - | Illumina acquisition of Grail wins support from GOP lawmakers, state AGs as FTC tries to block it | Republican lawmakers, a dozen state attorneys general and several advocacy groups voiced their support for Illumina’s acquisition of cancer-test developer Grail.
They argued in the briefs that the FTC overstepped its authority in trying to ... |
| - | This CEO has a promising startup but no visa | Deborah Zanforlin, CEO and cofounder of ConquerX
It takes a certain type of person to launch a healthcare startup. It’s a life — not a job — that is infinitely challenging and all-consuming. Failure lurks around every corner.
Deborah Zanfor... |
| - | Viome Life Sciences launches at-home oral/throat cancer test for consumers | Viome Life Sciences, a biotechnology company founded in 2016, has launched CancerDetect, a diagnostic test for oral and throat cancer that uses mRNA technology and an AI-powered platform, the company announced last week.
The test is a direc... |
| - | Liquid biopsy firm Thrive launches with $110M Series A round | A new company developing a liquid biopsy test has launched, and it has already completed enrollment in a study of more than 10,000 patients.
Cambridge, Massachusetts-based Thrive Earlier Detection launched Thursday with a $110 million Serie... |
| - | GRAIL Announces First Health System to Offer Galleri, Novel Multi-Cancer Early Detection Blood Test | MENLO PARK, Calif.--(BUSINESS WIRE)--Mar 2, 2021--
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced a partnership with leading health system Providence to advance the science a... |
| - | Grail validation data show highly accurate detection of cancers, tissues of origin | A test in development for early detection of cancers was able to pick up a dozen of the deadliest cancer types at stages I-IV with a high degree of accuracy while also determining where the tumor was located, according to validation data an... |
| - | Digital health investments reached record level in 2017 | Although their figures differ, StartUp Health and Rock Health both noted in their end-of-year digital health reports that dealflow reached a new peak in 2017. StartUp Health counted $11.5 billion on the back of 794 deals, partly because it ... |
| - | Illumina unveils plans to cut costs as it faces shrinking margins | Illumina unveiled plans to cut costs as it faces shrinking margins
The plans aim to reduce Illumina’s annualized run rate expenses by more than $100 million starting later this year, according to the company’s first-quarter earnings release... |
| - | Would Illumina’s acquisition of GRAIL constrict the expansion of the liquid biopsy space? | Earlier this year, the Federal Trade Commission’s (FTC) posed a roadblock in the path of sequencing giant Illumina’s $7.1 billion proposed acquisition of Grail, a healthcare company focusing on early cancer detection, and importantly, a 201... |
| - | Illumina hit with record $476 million fine for closing Grail deal without EU approval | European Union regulators fined Illumina a record 432 million euros ($476 million) for closing its acquisition of cancer test developer Grail without first securing regulatory approval.
A spokesperson for San Diego-based Illumina told CNBC ... |
| - | GRAIL and Quest Diagnostics Announce Collaboration to Support Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test | MENLO PARK, Calif.--(BUSINESS WIRE)--Feb 23, 2021--
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced an agreement with Quest Diagnostics (NYSE: DGX), the leading provider of di... |
| - | Genomics giant Illumina is looking beyond the sequencing box. But investors aren't sold on CEO Francis deSouza's 'legacy-defining' $8 billion gamble. | Illumina's CEO Francis deSouza. Illumina This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Illumina's CEO, Francis deSouza, is moving the gene-sequencing giant into drugs and diagnostics.
T... |
| - | Is too much money being invested in oncology? | Between venture capitalists flush with cash and corporate mergers and acquisitions, money is gushing into oncology.
The $1 billion-plus invested in Grail is the grand example, but every week, another big deal is announced. After spending $1... |
| - | Freenome nabs $160M to advance blood-based colorectal cancer test | Investors have poured boatloads of cash into liquid biopsy companies promising that their technology is the solution for non-invasive screening of early-stage cancer.
In the latest mega funding round, South San Francisco company Freenome ha... |
| - | Prepping for FDA approval, Grail is partnering with health systems to validate its pan-cancer test | There are many holy grails in the healthcare world: solving interoperability issues, achieving health equity and a universal patient record. Grail, the liquid biopsy company based in Menlo Park, California, is on another, equally challengin... |
| - | Oncology, rare diseases and too little genomic diversity: 3 themes from #JPM17 | As always, the J.P. Morgan Healthcare Conference played host to wider debates about the health and direction of the life sciences in 2017.
Drug pricing was part of the discussion (Trump made his splash mid-week). Gender diversity came to th... |
